Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan;103(1):e70016.
doi: 10.1002/jnr.70016.

The Intricate Interplay: Microbial Metabolites and the Gut-Liver-Brain Axis in Parkinson's Disease

Dayamrita Kollaparampil Kishanchand  1 , Athira Krishnan K A  1 , Krishnapriya Chandrababu  1 , Cyriac Abby Philips  2 , Unnikrishnan Sivan  3 , Baby Chakrapani Pulikaparambil Sasidharan  1   4
Affiliations
Review

The Intricate Interplay: Microbial Metabolites and the Gut-Liver-Brain Axis in Parkinson's Disease

Dayamrita Kollaparampil Kishanchand et al. J Neurosci Res. 2025 Jan.

Abstract

Parkinson's Disease (PD) is a neurodegenerative disorder marked by the depletion of dopaminergic neurons. Recent studies highlight the gut-liver-brain (GLB) axis and its role in PD pathogenesis. The GLB axis forms a dynamic network facilitating bidirectional communication between the gastrointestinal tract, liver, and central nervous system. Dysregulation within this axis, encompassing gut dysbiosis and microbial metabolites, is emerging as a critical factor influencing PD progression. Our understanding of PD was traditionally centered on neurodegenerative processes within the brain. However, examining PD through the lens of the GLB axis provides new insights. This review provides a comprehensive analysis of microbial metabolites, such as short-chain fatty acids (SCFAs), trimethylamine-N-oxide (TMAO), kynurenine, serotonin, bile acids, indoles, and dopamine, which are integral to PD pathogenesis by modulation of the GLB axis. Our extensive research included a comprehensive literature review and database searches utilizing resources such as gutMGene and gutMDisorder. These databases have been instrumental in identifying specific microbes and their metabolites, shedding light on the intricate relationship between the GLB axis and PD. This review consolidates existing knowledge and underscores the potential for targeted therapeutic interventions based on the GLB axis and its components, which offer new avenues for future PD research and treatment strategies. While the GLB axis is not a novel concept, this review is the first to focus specifically on its role in PD, highlighting the importance of integrating the liver and microbial metabolites as central players in the PD puzzle.

Keywords: GLB axis; Parkinson's disease; gut dysbiosis; gut‐brain axis; microbial metabolites.

PubMed Disclaimer

References

    1. Adhikary, S., A. Esmeeta, A. Dey, et al. 2024. “Impacts of Gut Microbiota Alteration on Age‐Related Chronic Liver Diseases.” Digestive and Liver Disease 56, no. 1: 112–122. https://www.sciencedirect.com/science/article/pii/S1590865823007144?via%....
    1. Agus, A., J. Planchais, and H. Sokol. 2018. “Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease.” Cell Host & Microbe 23: 716–724.
    1. Ahn, E. H., X. Liu, A. M. Alam, S. S. Kang, and K. Ye. 2023. “Helicobacter hepaticus Augmentation Triggers Dopaminergic Degeneration and Motor Disorders in Mice With Parkinson's Disease.” Molecular Psychiatry 28, no. 3: 1337–1350. https://www.nature.com/articles/s41380‐022‐01910‐2?fromPaywallRec=false.
    1. Apetauerova, D., P. Hildebrand, S. Scala, et al. 2021. “A Prospective Study of the Prevalence of Parkinsonism in Patients With Liver Cirrhosis.” Hepatology Communications 5: 323–333.
    1. Athauda, D., and T. Foltynie. 2016. “The Glucagon‐Like Peptide 1 (GLP) Receptor as a Therapeutic Target in Parkinson's Disease: Mechanisms of Action.” Drug Discovery Today 21: 802–818.

LinkOut - more resources